{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:02:55Z","timestamp":1782730975304,"version":"3.54.5"},"reference-count":45,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The overall incidence of malignancy in patients with end-stage kidney disease (ESKD) is reportedly higher compared to the general population. Cancer remains one of the dominant causes of death in these patients, due in part to uremia-induced impairment of tumor immune surveillance. Malignancy is one of the major limitations in the evaluation of potential kidney transplantation. This study aimed to assess the prevalence of cancer in hemodialysis population, particularly in relation to the waiting list. Materials and Methods: From the population of 5879 prevalent hemodialysis patients (60% men), 757 of them had a history of malignancy. In this population, 449 patients were actively waitlisted, and 4619 were not considered for potential kidney transplantation. Only 54 patients had unclear status in relation to active waiting list (during evaluation\/disqualification). We assessed demographic data, basal biochemical data, and comorbidities, including malignancy, in relation to age, sex, presence of metastasis, and being actively waitlisted. Results: Malignancy was reported in 13% of hemodialysis patients, 6% of which had metastatic disease. Patients with malignancy were older (p &lt; 0.001). More cases of cancer were observed in males (p = 0.02), who also had higher Charlson Comorbidity Index scores. Moreover, in patients with cancer, cardiovascular diseases were more common. They were also more malnourished (lower albumin, hemoglobin, lean mass) and more inflamed (higher ferritin, lower phosphorus). Only 27 patients with cancer were actively waitlisted, representing only 3.8% of this population. Patients with prior cancer on the active waiting list constituted 6% of all the waitlisted patients. Patients with a history of malignancy on the active waiting list were significantly younger, healthier, with significantly lower Charlson Comorbidity Index score, significantly lower ferritin, lower prevalence of diabetes, and higher blood pressure when compared to patients with malignancy who not listed for kidney transplantation. Conclusions: As malignancy became a more common comorbidity in dialysis patients, the elderly in particular, standardized cancer screening protocols should be promoted in dialysis units. Modern oncology has made huge progress, enabling the treatment of previously incurable cancers, as malignancy after kidney transplantation is considerably increased either due to de novo cancers or the recurrence of previous malignancy. Therefore, the evaluation of potential kidney transplant recipients, with tailored cancer screening and multidisciplinary evaluation, is strongly recommended. Besides a history of malignancy, the cardiovascular status also determines the eligibility for transplantation in dialysis patients. It is of paramount importance as the main cause of death in transplant recipients is cardiovascular death followed by malignancy.<\/jats:p>","DOI":"10.3390\/cancers17172782","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T14:18:49Z","timestamp":1756217929000},"page":"2782","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Malignancy in Dialysis Patients\u2014How Serious Is the Problem, Especially in Relation to Waiting List Status?"],"prefix":"10.3390","volume":"17","author":[{"given":"Letycja","family":"R\u00f3g","sequence":"first","affiliation":[{"name":"Department of Oncology, Medical University of Warsaw, ul. Banacha 1A, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7980-4842","authenticated-orcid":false,"given":"Jacek","family":"Zawierucha","sequence":"additional","affiliation":[{"name":"Fresenius Medical Care Polska S.A., 60-118 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Symonides","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hypertension and Vascular Diseases, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Marcinkowski","sequence":"additional","affiliation":[{"name":"Fresenius Medical Care Polska S.A., 60-118 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0142awomir Jerzy","family":"Ma\u0142yszko","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pathophysiology, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8701-8171","authenticated-orcid":false,"given":"Jolanta","family":"Ma\u0142yszko","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dialysis, and Internal Medicine, Medical University of Warsaw, ul. Banacha 1A, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"sfaf077","DOI":"10.1093\/ckj\/sfaf077","article-title":"Cancer risks in people on dialysis and kidney transplant recipients: A Catalan cohort study, 2003\u20132021","volume":"18","author":"Oliveras","year":"2025","journal-title":"Clin. Kidney J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3892\/mco.2016.952","article-title":"Cancer risk in patients receiving renal replacement therapy: A meta-analysis of cohort studies","volume":"5","author":"Shang","year":"2016","journal-title":"Mol. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"66601","DOI":"10.18632\/oncotarget.18094","article-title":"Cancer and the kidney: Dangereoux liasons or price paid for the progress in medicine?","volume":"8","author":"Kozlowski","year":"2017","journal-title":"Oncotarget"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/ndt\/gfy262","article-title":"An update on cancer after kidney transplantation","volume":"34","author":"Cheung","year":"2019","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/ckj\/sfac124","article-title":"The incidence of cancer recurrence and new cancer following commencement of dialysis","volume":"15","author":"Lim","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/ckj\/sfx122","article-title":"Risk factors associated with post-kidney transplant malignancies: An article from the Cancer-Kidney International Network","volume":"11","author":"Sprangers","year":"2018","journal-title":"Clin. Kidney J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1053\/j.ajkd.2019.12.018","article-title":"Cancer Screening in Patients Undergoing Maintenance Dialysis: Who, What, and When","volume":"76","author":"Rosner","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/tri.13464","article-title":"Significance of atypical urinary cytology in the evaluation of patients with end-stage renal disease for kidney transplantation\u2014A retrospective study","volume":"32","author":"Law","year":"2019","journal-title":"Transpl. Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0140-6736(20)30540-7","article-title":"The link between kidney disease and cancer: Complications and treatment","volume":"396","author":"Malyszko","year":"2020","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/ndt\/gfad160","article-title":"Challenges for optimal care in onconephrology","volume":"39","author":"Hanna","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1093\/ndt\/gfae142","article-title":"Cancer therapy in patients with reduced kidney function","volume":"39","author":"Karam","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s40620-024-02110-7","article-title":"Chemotherapy in patients with severely reduced glomerular filtration rate: Challenges and a call for improvement","volume":"38","author":"Karam","year":"2025","journal-title":"J. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1007\/s10147-023-02377-z","article-title":"Chapter 2: Indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022","volume":"28","author":"Nishiyama","year":"2023","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ki.1996.307","article-title":"A study of the quality of life and cost-utility of renal transplantation","volume":"50","author":"Laupacis","year":"1996","journal-title":"Kidney Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","article-title":"Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant","volume":"341","author":"Wolfe","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/TP.0000000000001651","article-title":"Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group","volume":"101","author":"Neuberger","year":"2017","journal-title":"Transplantation"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Yang, D., Thamcharoen, N., and Cardarelli, F. (2019). Management of Immunosuppression in Kidney Transplant Recipients Who Develop Malignancy. J. Clin. Med., 8.","DOI":"10.3390\/jcm8122189"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/TP.0000000000003136","article-title":"KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation","volume":"104","author":"Chadban","year":"2020","journal-title":"Transplantation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/ndt\/gfac239","article-title":"Malignancies in adult kidney transplant candidates and recipients: Current status","volume":"38","author":"Serkies","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/ajt.16318","article-title":"Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement","volume":"21","author":"Hammel","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.transproceed.2020.01.119","article-title":"Malignancy Prevalence in Waitlisted Potential Kidney Transplant Recipients Is Very Low Relative to Patients After Kidney Transplantation","volume":"52","author":"Wieliczko","year":"2020","journal-title":"Transplant. Proc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.transproceed.2022.01.025","article-title":"Malignancy Prevalence in the Dialyzed Population and in Waitlisted Potential Kidney Transplant Recipients","volume":"54","author":"Wieliczko","year":"2022","journal-title":"Transplant. Proc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1159\/000186652","article-title":"Incidence and mortality patterns of malignancy and factors affecting the risk of malignancy in dialysis patients","volume":"59","author":"Inamoto","year":"1991","journal-title":"Nephron"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0272-6386(89)80187-8","article-title":"Neoplasms in dialysis patients: A population-based study","volume":"14","author":"Port","year":"1989","journal-title":"Am. J. Kidney Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2232046","DOI":"10.1080\/0886022X.2023.2232046","article-title":"Cancer before and after the start of hemodialysis and association with mortality\u2014An Eastern-European multicenter study","volume":"45","author":"Gadalean","year":"2023","journal-title":"Ren. Fail."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"sfae430","DOI":"10.1093\/ckj\/sfae430","article-title":"Cancer diagnosis and prognosis after initiation of hemodialysis: Multicenter Japan CANcer and DialYsis (J-CANDY) study","volume":"18","author":"Toriu","year":"2024","journal-title":"Clin. Kidney J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s40620-019-00649-4","article-title":"Distribution and association of cancer with mortality in end-stage renal disease patients receiving dialysis","volume":"32","author":"Chinnadurai","year":"2019","journal-title":"J. Nephrol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/ndt\/gfx355","article-title":"Changes in co-morbidity pattern in patients starting renal replacement therapy in Europe-data from the ERA-EDTA Registry","volume":"33","author":"Ceretta","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kadatane, S.P., Satariano, M., Massey, M., Mongan, K., and Raina, R. (2023). The Role of Inflammation in CKD. Cells, 12.","DOI":"10.3390\/cells12121581"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1084\/jem.190.10.1367","article-title":"At the crossroads of inflammation and tumorigenesis","volume":"190","author":"Prives","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5414\/CN110656","article-title":"Pre-dialysis levels of inflammation and endotoxin in people receiving hemodialysis are not associated with blood pressure variability","volume":"98","author":"Dheda","year":"2022","journal-title":"Clin. Nephrol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/aam.aam_56_18","article-title":"Inflammation and cancer","volume":"18","author":"Singh","year":"2019","journal-title":"Ann. Afr. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Di Paola, R., De, A., Izhar, R., Abate, M., Zappavigna, S., Capasso, A., Perna, A.F., La Russa, A., Capasso, G., and Caraglia, M. (2023). Possible Effects of Uremic Toxins p-Cresol, Indoxyl Sulfate, p-Cresyl Sulfate on the Development and Progression of Colon Cancer in Patients with Chronic Renal Failure. Genes, 14.","DOI":"10.3390\/genes14061257"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Lim, Y.J., Sidor, N.A., Tonial, N.C., Che, A., and Urquhart, B.L. (2021). Uremic Toxins in the Progression of Chronic Kidney Disease and Cardiovascular Disease: Mechanisms and Therapeutic Targets. Toxins, 13.","DOI":"10.3390\/toxins13020142"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.transproceed.2015.04.073","article-title":"Cancer Screening of Renal Transplant Patients Undergoing Long-Term Immunosuppressive Therapy","volume":"47","author":"Demir","year":"2015","journal-title":"Transplant. Proc."},{"key":"ref_36","first-page":"941","article-title":"Comorbidities on kidney transplantation waiting list relative to the status of the potential recipient","volume":"14","author":"Malyszko","year":"2018","journal-title":"Arch. Med. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1432-2277.2005.00109.x","article-title":"Prevalence of cancer history prior to renal transplantation","volume":"18","author":"Fischereder","year":"2005","journal-title":"Transpl. Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.ajkd.2014.12.013","article-title":"Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996\u20132009","volume":"65","author":"Butler","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ki.2014.419","article-title":"Development and validation of a predictive mortality risk score from a European hemodialysis cohort","volume":"87","author":"Floege","year":"2015","journal-title":"Kidney Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1097\/TP.0000000000001659","article-title":"Association Between Pretransplant Cancer and Survival in Kidney Transplant Recipients","volume":"101","author":"Dahle","year":"2017","journal-title":"Transplantation"},{"key":"ref_41","unstructured":"(2025, August 14). Available online: https:\/\/www.eurotransplant.org\/cms\/mediaobject.php?file=Eurotransplant+JV+PDF.pdf."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Bossola, M., Di Napoli, A., Angelici, L., Bargagli, A.M., Cascini, S., Kirchmayer, U., Agabiti, N., Davoli, M., and Marino, C. (2023). Trend and determinants of mortality in incident hemodialysis patients of the Lazio region. BMC Nephrol., 24.","DOI":"10.1186\/s12882-023-03170-w"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1097\/TP.0000000000004694","article-title":"Cancer Mortality Among Solid Organ Transplant Recipients in the United States During 1987\u20132018","volume":"107","author":"Wang","year":"2023","journal-title":"Transplantation"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ajt.2022.11.006","article-title":"Mortality among solid organ transplant recipients with a pretransplant cancer diagnosis","volume":"23","author":"Hart","year":"2023","journal-title":"Am. J. Transplant."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1093\/ckj\/sfad141","article-title":"Prior cancer history and suitability for kidney transplantation","volume":"16","author":"Wong","year":"2023","journal-title":"Clin. Kidney J."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/17\/2782\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:33:07Z","timestamp":1760034787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/17\/2782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":45,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["cancers17172782"],"URL":"https:\/\/doi.org\/10.3390\/cancers17172782","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]}}}